RE: NEUROCHEM ALZHEMED RESULTS ............polaks
Hey Polaks.......off topic.....i just keep the bashers on ignore. ss has been on ignore for me for a long long time. Bashers add nothing to the discussion. Nothing of value and they just post gibberish to deflect their true intentions. Not to be trusted.
But back to Neurochems Farce........Bellini's been playing with those numbers for a long time, juggling them to try to suit his own purposes and then when he got the First Approvable Letter last year suggesting another Phaselll be done he refused to do the Phasell again and sent them in some of the missing data. Now this time he gets another Approvable Letter requesting another Phaselll be conducted and we'll see what he does.
I think the big thing here for Transition is because AZD-103 is in the same class of compounds that Alzhemed is, The Best Case Scenario for us has happened. If alzhemed was not approvable we could have taken quite a hit......even though AZD-103 is in no way connected to alzhmed but through a Compound Class.
Remember Transition ran AZD-103 through our Drug Discovery Optimol Small Molecule Screening Program to see if altering it could improve it in any way.........and any change to AZD-103 rendered it useless. The origial researchers at U of TO got it absolutely right in the 10 years that they researched it...... but we had to check it anyways.....lol.
So now with AZD-103 going into Phasell this Fall and Bellini dragging his heels not wanting or not being able to go to raise money to afford to conduct another Phaselll we are not so far behind in the Amyloid Beta Buster Race!! Good News I say........Good News!!
GLA